Desmosine

Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update

Retrieved on: 
Monday, October 23, 2023

LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on recent program developments and third quarter 2023 financial information.

Key Points: 
  • LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on recent program developments and third quarter 2023 financial information.
  • The Phase 3 portion of the study is currently enrolling approximately 195 patients at 50 sites across 12 countries.
  • There was no difference in the proportion of patients with treatment-related Adverse Events (AEs) between the alvelestat and placebo arms.
  • The data from the ATALANTa study are expected to further support the ongoing partnering process for the alvelestat Phase 3 program.

Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma’s Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference

Retrieved on: 
Tuesday, May 23, 2023

In line with previous guidance, Mereo is continuing to explore potential partnerships to fund the Phase 3 development of alvelestat.

Key Points: 
  • In line with previous guidance, Mereo is continuing to explore potential partnerships to fund the Phase 3 development of alvelestat.
  • Headache is a known adverse event associated with alvelestat and is being addressed through dose-escalation during initiation of alvelestat treatment.
  • The secondary endpoints were the proportion of patients with NE below the limit of quantitation and PK, safety and tolerability.
  • Exploratory endpoints included rate of acute exacerbations of COPD, pulmonary function tests, St George’s Respiratory Questionnaire, inflammatory and lung damage biomarkers.

CABIO showcases the new products and Ready-to-Market solutions at Vitafoods Europe 2023

Retrieved on: 
Tuesday, May 9, 2023

GENEVA, May 9, 2023 /PRNewswire/ -- On May 9-11, 2023, CABIO Biotech (Wuhan) Co., Ltd (CABIO), a leading Chinese biotechnology company, participates in the three-day Vitafoods Europe held in Geneva, Switzerland.

Key Points: 
  • GENEVA, May 9, 2023 /PRNewswire/ -- On May 9-11, 2023, CABIO Biotech (Wuhan) Co., Ltd (CABIO), a leading Chinese biotechnology company, participates in the three-day Vitafoods Europe held in Geneva, Switzerland.
  • It's noticeable on-site that aging resistance, immunity enhancement, intestinal well-being, and sustainability are in the limelight of the sector.
  • In its in-depth discussion themed with Ready-to-Market Solutions, CABIO exchanges ideas with customers and partners concerning immunity enhancement, intestinal wellbeing, all-new ingredients enabling beauty from within, and innovative solutions.
  • As the global expert in high-end nutrient and innovative solutions, CABIO has always dedicated itself to human nutrition and health.

CABIO showcases the new products and Ready-to-Market solutions at Vitafoods Europe 2023

Retrieved on: 
Tuesday, May 9, 2023

GENEVA, May 9, 2023 /PRNewswire/ -- On May 9-11, 2023, CABIO Biotech (Wuhan) Co., Ltd (CABIO), a leading Chinese biotechnology company, participates in the three-day Vitafoods Europe held in Geneva, Switzerland.

Key Points: 
  • GENEVA, May 9, 2023 /PRNewswire/ -- On May 9-11, 2023, CABIO Biotech (Wuhan) Co., Ltd (CABIO), a leading Chinese biotechnology company, participates in the three-day Vitafoods Europe held in Geneva, Switzerland.
  • It's noticeable on-site that aging resistance, immunity enhancement, intestinal well-being, and sustainability are in the limelight of the sector.
  • In its in-depth discussion themed with Ready-to-Market Solutions, CABIO exchanges ideas with customers and partners concerning immunity enhancement, intestinal wellbeing, all-new ingredients enabling beauty from within, and innovative solutions.
  • As the global expert in high-end nutrient and innovative solutions, CABIO has always dedicated itself to human nutrition and health.

Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease

Retrieved on: 
Tuesday, March 21, 2023

LONDON, March 21, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (Mereo or the Company), a clinical-stage biopharmaceutical company focused on rare diseases, today announced regulatory feedback following recent end-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) related to its alvelestat program for the treatment of alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD).

Key Points: 
  • Each of the proposed primary endpoints has been shown to be associated with reductions in certain disease activity biomarkers.
  • The association of desmosine reduction with lung density measured by CT scan was demonstrated in published clinical data in AATD 1.
  • Mereo also believes that this proposed study, if successful, will support more productive initial reimbursement discussions with payors following potential regulatory approvals.
  • A live audio webcast of the call can be accessed through the Investors section of the Company’s website at www.mereobiopharma.com/investors .

CEO’s of NIO, NEXCF, MREO, and AIMLF Advancing Next Wave of Multi-Billion Dollar Growth Opportunities in Web 3.0, Wearables, Pharma, and Electric Vehicles.

Retrieved on: 
Tuesday, June 21, 2022

Todays emerging technologies and lifestyle megatrends are creating billion dollar opportunities for disruptive innovation in how we live, work and play.

Key Points: 
  • Todays emerging technologies and lifestyle megatrends are creating billion dollar opportunities for disruptive innovation in how we live, work and play.
  • In 2022, we plan to open more than 100 new sales outlets and over 50 new service centers and authorized service centers.
  • NexTech is emerging as the on ramp to the Metaverse and Web 3.0 for the $5.5 trillion e-commerce industry.
  • AIMLF is reporting advancing growth at its portfolio company Tech2Heal, a European mental health app innovator.

Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from “ASTRAEUS” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema

Retrieved on: 
Monday, May 9, 2022

LONDON and REDWOOD CITY, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced positive top-line efficacy and safety results from “ASTRAEUS” a Phase 2 study of the investigational oral neutrophil elastase (NE) inhibitor, alvelestat (MPH-966), in patients with severe alpha-1 antitrypsin deficiency-associated emphysema.

Key Points: 
  • Consistent with the known safety profile of alvelestat, no safety signals were observed in adverse event (AE) monitoring.
  • Most AEs were mild to moderate, including within Adverse Events of Special Interest (AESI) which were observed in 23 subjects.
  • Prior to Mereo BioPharma licensing alvelestat from AstraZeneca (AZ), trials across COPD, bronchiectasis and cystic fibrosis (CF) had been performed.
  • Mereo reported a positive Phase 1b/2 trial in COVID-19 which was completed in 2021 and showed alvelestat was safe and well tolerated.

Data from Investigator-sponsored Trial of Mereo BioPharma’s alvelestat in Bronchiolitis Obliterans Syndrome (BOS) Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Thursday, November 4, 2021

This was the first evidence of elevated elastase activity as detected by elastin breakdown in patients with BOS and chronic GVHD.

Key Points: 
  • This was the first evidence of elevated elastase activity as detected by elastin breakdown in patients with BOS and chronic GVHD.
  • Treatment with alvelestat was associated with progressive reduction of plasma desmosine levels over 8 weeks of within-subject dose escalation and reduction stimulated neutrophil elastase activity.
  • As the disease progresses, the bronchioles may become damaged and inflamed, leading to extensive scarring and blockage of the airways.
  • You should not place undue reliance on any forward-looking statements, which speak only as of the date hereof.

Mereo BioPharma Announces Positive Desmosine Biomarker Data from an Interim Analysis of an Investigator Initiated Study of alvelestat in Bronchiolitis Obliterans Syndrome (BOS)

Retrieved on: 
Wednesday, June 2, 2021

Interim data from the first seven patients in this open-label study were presented at the 2020 American Society of Hematology (ASH) Annual Meeting in December 2020.

Key Points: 
  • Interim data from the first seven patients in this open-label study were presented at the 2020 American Society of Hematology (ASH) Annual Meeting in December 2020.
  • In this phase 1 study, maximum-tolerated dose (MTD) was not reached and alvelestat was well tolerated.
  • Notably, two patients had improvement in forced expiratory volume in one second (FEV1) of 9%, and four patients experienced improvement in symptoms.
  • Subsequent analysis of the elastin breakdown biomarker desmosine, has recently been completed.